Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Multicenter Study With Optional Open-Label Extension to Evaluate the Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

NCT06848348 is registered in ClinicalTrials.gov with Dogwood Therapeutics Inc. as lead sponsor.

NCT NCT06848348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Multicenter Study With Optional Open-Label Extension to Evaluate the Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Lead sponsor
Dogwood Therapeutics Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 21, 2025
Completion date
December 31, 2026
Enrollment
240 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced neuropathic pain, chemotherapy induced pain, chemotherapy induced pain neuropathy